Horizon’s phase 3 trial for Teprotumumab in active thyroid eye disease meets primary endpoint
The study met its primary endpoint, showing more patients treated with teprotumumab compared with placebo had a meaningful improvement in proptosis, or bulging of the eye: 82.9 percent